⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NXL News
Nexalin Technology, Inc. Common Stock
Form 8-K
sec.gov
NXL
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
globenewswire.com
NXLIW
NXL
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
globenewswire.com
NXLIW
NXL
Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
accessnewswire.com
NXL
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care
globenewswire.com
NXLIW
NXL
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
globenewswire.com
NXLIW
NXL
Nexalin Technology Receives Nasdaq Listing Status Notification
globenewswire.com
NXL
Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
globenewswire.com
NXL
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
globenewswire.com
NXL
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
globenewswire.com
NXL